Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in ... added to background maximal standard-of-care inhaled therapy in adults with uncontrolled COPD ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Sanofi SNY and partner Regeneron REGN announced that the FDA approved Dupixent (dupilumab) for the treatment of chronic ...

Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial ...

Participants were on standard-of-care medicines with medium-to-high doses of inhaled ... and asthma control (ACQ-5). In partnership with Regeneron, Sanofi is exploring itepekimab, a fully human ...

This is a study that could potentially change the standard of care," Berger said ... Future of Healthcategory Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition April 18, 2025 Future ...

Itepekimab: expanding clinical studies beyond COPD into chronic rhinosinusitis In partnership with Regeneron ... About Sanofi We are an innovative global healthcare company, driven by one purpose ...

All patients were treated with standard-of-care therapy, including medium-to-high doses of ... with COPD is expected to launch later this year. In collaboration with Regeneron, Sanofi announced the ...